Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 25;14(1):103.
doi: 10.1038/s41408-024-01079-7.

Are thrombosis, progression, and survival in ET predictable?

Ghaith Abu-Zeinah #  1 , Katie Erdos #  2 , Neville Lee  2 , Ahamed Lebbe  3 , Imane Bouhali  3 , Mohammed Khalid  3 , Richard T Silver  2 , Joseph M Scandura  2
Affiliations

Are thrombosis, progression, and survival in ET predictable?

Ghaith Abu-Zeinah et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Thrombosis-free (TFS) and myelofibrosis-free survival (MFS) by driver mutation.
A TFS of ET patients stratified by driver mutation. B MFS of ET patients stratified by driver mutation.
Fig. 2
Fig. 2. Overall survival (OS) models for ET patients.
A OS of ET patients stratified by triple A risk. B OS of ET patients stratified by IPSET-survival risk.
See this image and copyright information in PMC

References

    1. Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124:2507–13. doi: 10.1182/blood-2014-05-579136. - DOI - PMC - PubMed
    1. Barbui T, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, et al. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J. 2015;5:e369–e369. doi: 10.1038/bcj.2015.94. - DOI - PMC - PubMed
    1. Passamonti F, Thiele J, Girodon F, Rumi E, Carobbio A, Gisslinger H, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood. 2012;120:1197–201. doi: 10.1182/blood-2012-01-403279. - DOI - PubMed
    1. Tefferi A, Guglielmelli P, Lasho TL, Coltro G, Finke CM, Loscocco GG, et al. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Br J Haematol. 2020;189:291–302. doi: 10.1111/bjh.16380. - DOI - PubMed
    1. Tefferi A, Loscocco GG, Farrukh F, Szuber N, Mannelli F, Pardanani A, et al. A globally applicable “triple A” risk model for essential thrombocythemia based on age, absolute neutrophil count, and absolute lymphocyte count. Am J Hematol. 2023;98:1829–37. doi: 10.1002/ajh.27079. - DOI - PubMed

Publication types